A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 10, Pages 1932-1944
Publisher
Springer Nature
Online
2014-10-08
DOI
10.1038/bjc.2014.497
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
- (2013) Arif Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials
- (2013) Yuan Ji et al. JOURNAL OF CLINICAL ONCOLOGY
- Anticancer IGF1R classes take more knocks
- (2013) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models
- (2013) Cathy C. Zhang et al. Stem Cells Translational Medicine
- Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma
- (2012) M. M. Mita et al. ANNALS OF ONCOLOGY
- Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)
- (2012) S. Schmitz et al. ANNALS OF ONCOLOGY
- Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
- (2012) V. M. Macaulay et al. ANNALS OF ONCOLOGY
- Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
- (2012) J. Gao et al. CANCER RESEARCH
- The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
- (2012) M. Pollak CLINICAL CANCER RESEARCH
- Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group
- (2012) Maria Grazia Daidone et al. EJC SUPPLEMENTS
- Targeting the Notch Pathway: Twists and Turns on the Road to Rational Therapeutics
- (2012) Jon C. Aster et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
- (2012) Ian Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
- (2012) D. Yee JNCI-Journal of the National Cancer Institute
- Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL
- (2012) Samuel Gusscott et al. LEUKEMIA RESEARCH
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2011) F. Atzori et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
- (2011) Gordon John Sampson Rustin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling
- (2011) Hind Medyouf et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
- (2010) Andrey Loboda et al. BMC Medical Genomics
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
- (2010) J. E. Dancey et al. CLINICAL CANCER RESEARCH
- A modified toxicity probability interval method for dose-finding trials
- (2010) Yuan Ji et al. Clinical Trials
- PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541
- (2010) Daniel Hägerstrand et al. NEURO-ONCOLOGY
- Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway
- (2010) S Eliasz et al. ONCOGENE
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
- (2009) Paul Haluska et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma
- (2009) S. Avnet et al. CANCER RESEARCH
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- (2009) David Olmos et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor
- (2008) Matthieu Broussas et al. INTERNATIONAL JOURNAL OF CANCER
- Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis
- (2008) Mari-Anne Rowlands et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search